El Punt Avui, La Razón, El Periódico, El Economista, among other media, have published an article about the research that was financed with the 12 million euros collected in TV3’s 2012 Marató (telethon) dedicated to cancer. La Marató has highlighted, among others, two IRB Barcelona projects that were awarded funding. On the one hand, Núria López-Bigas developed the "Cancer Genome Interpreter", a platform that allows better selection of treatments for cancer and the prediction of patient response. And on the other, Salvador Aznar Benitah led a project addressing metastasis and its relation to the consumption of dietary fat.
Link to El Periódico
Link to El Economista
Tot Barcelona, e-notícies and El Plural have published an interview with Begoña Cánovas, a postdoctoral researcher at IRB Barcelona, who, thanks to a grant from "la Caixa", has been part of the team of researchers that detected the protein that fuels the survival of a type of breast cancer. "The day they gave me the first fellowship, I couldn’t believe it. I felt great and my parents jumped for joy when they found out. When you see all the applications, you feel like it's a lottery and you think you have no chance of winning, but it's worth trying, "said Cánovas.
Cope, ABC, La Rioja, among other media, have published an article about the inscriptions to the IV Women's Race for Research from Asociación Española Contra el Cáncer (AECC). The resources obtained from this race will be used to finance two predoctoral grants at two institutions in La Rioja. Also, the project "Research on the impact of senescence influenced by inflammation as a therapy on cancer stem cells" led by Marta Kovatcheva, researcher at IRB Barcelona, will be financed.
The web Hidden Nature has published an article about the 10 investigations that they considered to be the most important ones published in 2018. One of them refers to epigenetic therapies and mentions research research that supports and rejects them. In this regard, they mention the study led by Salvador Aznar Benitah at IRB Barcelona and published in Nature Cell Biology. The study in question concludes that care must be taken with drugs that inhibit epigenetic factors as they could cause the appearance of aggressive tumours.
